1 company and 1 research report found for "arGEN-X"
No sector reports have been found.
arGEN-X's novel approach to developing therapeutic antibodies has already generated five candidates. The €42m proceeds from the July 2014 IPO (4...
Forgotten your login?
Registered office: Edison Investment Research Limited, 280 High Holborn, London, WC1V 7EE UK. Company no. 4794244. VAT no. 815041270
© 2017 All rights reserved. Edison Investment Research is authorised and regulated by the Financial Conduct Authority.
This site requires cookies in order to give you the best user experience.
Find out more